StockData
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc. (LUCD) stock

LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3034% above fair value
$0.40+0.00 (+0.30%)

Close on Nov 17, 2026Market cap $81.09MP/E –Yield –

Lucid Diagnostics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Lucid Diagnostics's price to sales ratio was 13.4× on Nov 11, 2026, against 31.5× a year earlier. Over the last 5 years it ranged from 10.1× to 261.2×, with a median of 32.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202613.4×−19.1
2025Dec 31, 202532.4×+22.4
2024Dec 31, 202410.1×−29.7
2023Dec 29, 202339.8×−49.3
2022Dec 30, 202289.1×–

More Lucid Diagnostics figures

See a number that looks wrong?